AD1 Holdings Limited

AD1

AD1 Holdings Ltd. provides an on-line database and search platform to link employers and job candidates. The company is headquartered in Hawthorn, Victoria. The company went IPO on 2016-06-23. The firm builds, manages, and acquires software businesses that develop specialized software solutions to address the specific needs of the global workforce. The firm operates in two main verticals: HR Services and Niche Services. Under HR services the Company provides talent recruitment solutions in the form of ApplyDirect and mentoring products under the Art of Mentoring banner. ApplyDirect provides customer-branded recruitment marketing platforms and related digital services. Jobtale provides a purpose-built recruitment platform that organizations can use to create appealing and informative job ads to attract top talent. Its Utility software services provides a suite of software solutions that support energy retailers to optimize their operations from billing and payments to customer relationship management and end-to-end customer portals.

Acumentis Group Limited

ACU

Acumentis Group Ltd. engages in the provision of valuation, research, and advisory services in relation to property and businesses. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-05. The firm provides commercial and residential valuations, research, and property advice to various homeowners, investors, developers, and lenders. The company offers property valuation, insurance valuation, and advisory services to clients, including banks and financial institutions, property developers, property trusts, government, lawyers, accountants, real estate agents and independent retailers. Its services include quantity surveying, acquisition and compensation, capital gains tax, family law and legal, fund forecasts, illicit substance screening, insurance valuation, litigation and legal advisory services, property buyers’ agencies, self-managed super fund (SMSF) property valuation, stamp duty assessments, tax depreciation schedules and tenant representation. The firm serves property classes such as residential, commercial, rural, agribusiness and government portfolios.

Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The firm is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.